Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 125-132

  Khan, Masood A ^a,b   Owais, Mohd ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Antifungal agents; C. albicans; Erythrocytes; Renal function tests

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; TUFTSIN; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; ERYTHROCYTE; FEMALE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KIDNEY FUNCTION TEST; MOUSE; NEPHROTOXICITY; NONHUMAN; PHARMACODYNAMICS; RELIABILITY; SERUM; TOXICITY TESTING; UREA BLOOD LEVEL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDIASIS; DEOXYCHOLIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG STABILITY; IMMUNOLOGIC FACTORS; LIPOSOMES; MICE; MICE, INBRED BALB C; TUFTSIN;

EID: 33748036711     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl177     Document Type: Article

References (22)

1. Lupetti A, Danesi R, Campa M et al. Molecular basis of resistance to azole antifungals. Trends Mol Med 2002; 8: 76-81.
2. Sanglard D, Ischer F, Calabrese D et al. Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updates 1998; 1: 255-65.
3. Sterling TR, Merz WG. Resistance to amphotericin B: Emerging clinical and microbiological patterns. Drug Resist Updates 1998; 1: 161-5.
4. Wey SB, Mori M, Pfaller MA et al. Hospital-acquired candidemia. The attributable mortality and excess length of stay. Arch Intern Med 1988; 148: 2642-5.
5. Gibbs WJ, Drew RH, Perfect JR. Liposomal amphotericin B: Clinical experience and perspectives. Expert Rev Anti Infect Ther 2005; 3: 167-81.
6. Ostrosky-Zeichner L, Marr KA, Rex JH et al. Amphotericin B: Time for a new 'gold standard'. Clin Infect Dis 2003; 37: 415-25.
7. van Etten EW, Otte-Lambillion M, van Vianen W et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. J Antimicrob Chemother 1995; 35: 509-19.
8. Siemion IZ, Kluczyk A. Tuftsin: On the 30-year anniversary of Victor Najjar's discovery. Peptides 1999; 20: 645-74.
9. Trevisani F, Castelli E, Foschi FG et al. Impaired tuftsin activity in cirrhosis: Relationship with splenic function and clinical outcome. Gut 2002; 50: 707-12.
10. Khan MA, Faisal SM, Haque W et al. Immunomodulator tuftsin augments antifungal activity of Amp B against experimental murine Candidiasis. J Drug Target 2002; 10: 185-92.
11. Khan MA, Nasti TH, Saima K et al. Co-administration of immuno-modulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice. FEMS Immunol Med Microbiol 2004; 41: 249-58.
12. Owais M, Krishnakumar B, Jain RK et al. Tuftsin bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett 1993; 326: 56-8.
13. Singleton WS, Gray MS, Brown ML. A method for adsorbent fractionation of cottonseed oil for experimental intravenous fat emulsions. J Am Oil Chem Soc 1965; 42: 53-6.
14. Gupta CM, Haq W. Tuftsin-bearing liposomes as carriers of antibiotics in treatment of macrophage infections. Methods Enzymol 2005; 391: 291-304.
15. National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing for Yeasts: Approved Standard M27-A. NCCLS, Wayne, PA, USA, 1997.
16. Gupta CM, Puri A, Jain RK et al. Protection of mice against Plasmodium berghei infection by a tuftsin derivative. FEBS Lett 1986; 205: 351-4.
17. Hossain MA, Maesaki S, Razzaque MS et al. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B. J Antimicrob Chemother 2000; 46: 263-8.
18. McKim SE, Gabele E, Isayama F et al. Inducible nitric oxide synthase is required in alcohol-induced liver injury: Studies with knockout mice. Gastroenterology 2003; 125: 1834-44.
19. Legrand P, Romero EA, Cohen BE et al. Effects of aggregation and solvent on the toxicity of Amphotericin B on human erythrocytes. Antimicrob. Agents Chemother 1992; 36: 2518-22.
20. Wasan KM, Mortan RE, Rosenblum MG et al. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high density lipoproteins: Role of lipid transfer protein. J Pharm Sci 1994; 83: 1006-10.
21. Adler-Moore J. Ambisome targeting to fungal infections. Bone Marrow Transplant 1994; 14 Suppl 5: S3-7.
22. Perkins WR, Minchey SR, Boni LT et al. Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim Biophys Acta 1992; 1107: 271-81.